Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy.
Ronner E, Boersma E, Laarman GJ, Somsen GA, Harrington RA, Deckers JW, Topol EJ, Califf RM, Simoons ML. Ronner E, et al. Among authors: topol ej. J Am Coll Cardiol. 2002 Jun 19;39(12):1924-9. doi: 10.1016/s0735-1097(02)01897-1. J Am Coll Cardiol. 2002. PMID: 12084589 Free article. Clinical Trial.
Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy).
Breeman A, Mercado N, Lenzen M, van den Brand MM, Harrington RA, Califf RM, Topol EJ, Simoons ML, Boersma E; PURSUIT Investigators. Breeman A, et al. Among authors: topol ej. Cardiology. 2002;98(4):195-201. doi: 10.1159/000067321. Cardiology. 2002. PMID: 12566649 Clinical Trial.
Aspirin dose and six-month outcome after an acute coronary syndrome.
Quinn MJ, Aronow HD, Califf RM, Bhatt DL, Sapp S, Kleiman NS, Harrington RA, Kong DF, Kandzari DE, Topol EJ. Quinn MJ, et al. Among authors: topol ej. J Am Coll Cardiol. 2004 Mar 17;43(6):972-8. doi: 10.1016/j.jacc.2003.09.059. J Am Coll Cardiol. 2004. PMID: 15028352 Free article.
Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial.
Ottervanger JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM, James S, Topol E, Wallentin L, Simoons ML; GUSTO IV-ACS Investigators. Ottervanger JP, et al. Circulation. 2003 Jan 28;107(3):437-42. doi: 10.1161/01.cir.0000046487.06811.5e. Circulation. 2003. PMID: 12551868 Clinical Trial.
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ. Lincoff AM, et al. Among authors: topol ej. J Am Coll Cardiol. 1997 Jul;30(1):149-56. doi: 10.1016/s0735-1097(97)00110-1. J Am Coll Cardiol. 1997. PMID: 9207636 Free article. Clinical Trial.
The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
Narins CR, Miller DP, Califf RM, Topol EJ. Narins CR, et al. Among authors: topol ej. J Am Coll Cardiol. 1999 Mar;33(3):647-53. doi: 10.1016/s0735-1097(98)00620-2. J Am Coll Cardiol. 1999. PMID: 10080464 Free article. Clinical Trial.
1,208 results